Unilever to acquire US-based electrolyte drink manufacturer Liquid I.V.

TAGS

Unilever has signed a deal to acquire Liquid I.V, a US-based health-science nutrition and wellness company, for an undisclosed price.

Based in El Segundo, California, Liquid I.V. was established by entrepreneur Brandin Cohen in 2012.

Liquid I.V.’s electrolyte drink mixes leverage Cellular Transport Technology (CTT) which is said to boost the quick absorption of water and other important nutrients into the bloodstream.

As per the guidelines of the World Health Organization for the clinically proven Oral Rehydration Solution (ORS), that prevents and also treats dehydration, a single serving of Liquid I.V. can deliver up to two-three times the hydration of water alone, said Unilever.

See also  Infosys helps UNDP deploy Quantum Global Digital Management System

Liquid I.V. is said to offer a 360-degree approach to wellness with a product line that includes Hydration, Energy and Sleep. It is also non-GMO, vegan, gluten free, and also free from soy and dairy.

Unilever to acquire US-based electrolyte drink manufacturer Liquid I.V.

Unilever to acquire US-based electrolyte drink manufacturer Liquid I.V. Photo courtesy of Unilever.

Fabian Garcia – President of Unilever North America said: “Liquid I.V. is an impressive and innovative brand in the fast-growing health, wellness and personal nutrition space. Liquid I.V. shares Unilever’s purpose to improve people’s health and wellbeing, as well as our ambition to create sustainable products that have a positive social impact.

See also  Hijab controversy at Kansas Chipotle sparks major legal battle

“We are delighted to welcome Liquid I.V. to Unilever’s portfolio of purpose-driven brands.”

Liquid I.V. will continue to be headquartered in El Segundo and led by Brandin Cohen, who will continue as CEO and Founder.

Brandin Cohen said: “We are excited to work together with Unilever to scale the brand and amplify Liquid I.V.’s mission to help people everywhere live better lives – to optimise the body, hydrate those in need, and better the planet.”

See also  Protagonist Therapeutics raises $22m equity financing from BVF Partners

The deal is subject to regulatory approvals and meeting of customary closing conditions.

CATEGORIES
TAGS
Share This